 Leap Therapeutics, Inc. NASDAQ: LPTX, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters option to purchase additional shares from Leaps previously announced public offering. After giving effect to the full exercise of the option, the aggregate gross proceeds to Leap from this offering were approximately 51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap. 